PROCESS FOR THE PREPARATION OF 3-(1-HYDROXYETHYL)-AZETIDINONES

Abstract: Disclosed is a stereocontrolled process for the preparation of 3-(1-hydroxyethyl) azetidinones which are useful in the synthesis of thienamycin and its analogues.

Description: PROCESS FOR THE PREPARATION OF 3- (l-HYDROXYETHYL) - AZETIDINONES BACKGROUND OF THE INVENTION This invention relates to a stereocontrolled process for the preparation of certain 3-(l-hydroxyethyl)-azetidinones 4 which are useful in the synthesis of the antibiotic thienamycin and antibiotic, side chain analogues thereof. The process may be summarized as follows: EMI1.1 Relative to the above scheme, starting materials may be classified into seven (7) groups according to the definition of R1 and R2. I. R1 is CH=CH2; R2 is hydrogen or a protecting group; II. RÚ is CH2CH=CH2; Rê is hydrogen or a protecting group; III. RÚ is EMI2.1 R2 is hydrogen or a protecting group; IV. RÚ is EMI2.2 R is.hydrogen or Åa protecting group; V. R1 and R2 are joined to form: EMI2.3 VI. RÚ is CH2CH2OR ; R and Rê are selected form hydrogen or a protecting group; VII. RÚ is CH2CH=CHR ; Rê is hydrogen or a protecting group. Relative to categories III and IV, Ra, b and RC are independently chosen from alkyl having 1-6 carbon atoms, aralkyl and aryl; wherein the aryl moiety is phenyl. Typically, Ra, b and Rc are chosen from groups such as methyl, ethyl, benzyl, ethoxybenzyl, trityl, isopropyl, t-butyl, and phenyl, for example. Further, Ra and Rb may be joined together to form a radical such as -(CH2)3- to bridge the two sulphur atoms; this same provision for joinder also exists for Group III wherein any pair of Ra, Rb or Rc may be joined. Relative to Group IV and the moiety -Si(Rc)3, it should be noted that the three (3) Rc groups are independently chosen and need not be identical. Relative to VII, R0 is alkyl, aralkyl, cycloalkyl, or Cycloalkylalkyl Finally, relative to Group V, Rg and Rh are independently chosen from alkyl having 1-6 carbon atoms such as methyl, ethyl, isopropyl and the like; further R9 and Rh may be joined together to form, counting the carbon atom to which they are attached, a carbocyclic ring having 3-6 carbon atoms. .For categories I-VII, the precise identity of protecting groups R2 and R3 (VI) is not critical, provided only that the groups do not interfere with the indicated course of reaction. However, triorganosilyl groups and groups such as 2-tetrahydropyranyl are preferred. Representative of such silyl protecting groups are those wherein the organo moiety is chosen from phenyl and alkyl having 1-6 carbon atoms, such as trimethylsilyl, t-butyldimethylsilyl, triphenylsilyl, and the like. The groups I-EI which comprise the final product 4 of the process of the present invention: EMI3.1 are encountered in various schemes for the total synthesis of thienamycin. Some of these schemes, which demonstrate the utility of4, are published; others are recited in pending U.S. Patent Applications. These published and pending documents are identified below and are incorporated hereip by reference. Groups I, V and VI falling under genus 4 are fully disclosed as to identity and utility in German Otfenlegungsschrift 2751597 published 24 May 1978 which is incorporated herein by reference: EMI4.1 wherein R2 and R3 are defined above. The azetidinones of group III under the genus of 4 are defined as to identity and utility in European Patent Application Publication 007973 (application 79101307.1, filed 1 May 1979! which is incorporated herein by reference: EMI5.1 wherein Rê, Ra, Rb and Rc are as defined above. Group II falling under genus 4 is disclosed as to identity and utility in co-pending, commonly assigned U.S. Patent Application Serial Number 059842 filed 23 July 1979 of Christensen, Ratcliffe and Salzmann; this application, for the purpose indicated, is incorporated herein by reference: EMI6.1 Group VII falling under genus 4 is disclosed as to identity and utility in co-pending, commonly assigned U.S. Patent Application Serial Number 059843 filed 23 July 1979 of Christensen, Ratcliffe and Salzmann; this application, for the purpose indicated, is incorporated herein by reference: EMI7.1 wherein X is alkyl having 1-6 carbon atoms, cycloalkyl having 3-6 carbon atoms, cycloalkylalkyl having 4-12 carbon atoms and phenylalkyl having 7-12 carbon atoms. Group IV falling under genus 4 is disclosed as to identity and utility in co-pending, commonly assigned U.S. Patent Application Serial Number 059844 filed 23 July 1979 of Christensen, Ratcliffe and Salzmann; this application, for the purpose indicated, is incorporated herein by reference. EMI8.1 wherein Rê, Ra, Rb and RC are defined above. DETAILED DESCRI; TION OF THE INVENTION Relative to Diagram I, above, the alkylation reaction 1 # 2 is accomplished by treating 1 in a solvent such as tetrahycrofuran, dimethoxyethane, diethylether, hexamethylphosphoramide, glyme, dimethylforamide, dimethylsulfoxide, toluene, N,N,N',N'-tetramethylethylene diamine, or the like at a temperature of from -100 to 0 C with a strong base such as lithium diisopropylamide, lithium hexamethyldisilizide, mesitylithium, lithium 2,2,6, 6-tetramethylpiperidide, potassium hydride, sodium amide, t-butyl lithium, s-butyl lithium, potassium triphenylmethide, potassium hexamethyldisilizide or the like followed by the addition of an equivalent to 10-fold excess of acetaldehyde. This reaction gives a mixture of isomers from which the desired trans-R form (4) can be conveniently separated by chromatography or crystallization. In the alternative, 2 can be oxidized to 3 followed by reduction to 4. The oxidation 2 # 3 is accomplished with an oxidizing agent; representative of such non-critical oxidizing agents are: dipyridinium chromium (VI) oxide, trifluoroacetic anhydride-dimethylsulfoxide-triethylamine, pyrimidinium dichromate, aceticanhydride-dimethylsulfoxide, oxalyl chloride-dimethylsulfoxide-triethylamine, N-chlorosuccinimide-dimethylsulfide, Amberlyst A-25/HCrO4, chromium trioxide-3,5-dimethylpyrazole, methanesulfonic anhydride-dimethylsulfoxide-triethylamine, pyridinium chlorochromate, pyridinium dichromate, dicyclohexyldiimide dimethylsulfoxide, in a solvent such as methylene chloride, acetonitrile, hexamethylphosphoramide, toluene, dimethylformamide, dimethylsulfoxide, or the like at a temperature of from -78 to 250C for from 5 minutes to 5 hours. The reduction 3 - > 4 is accomplished by contacting 3 with a reducing agent such as potassium tri(sec-butyl)-- borohydride, lithium tri(sec-butyl)borohydride, sodium borohydride, sodium tris (methoxyethoxy) aluminum- hydride, zinc borohydride, potassium borohydride, lithium triethylborohydride, lithium tri-n-butylborohydride, lithium trisiamylborohydride, trimethyl-tert-butylaminomagnesium hydride, 2, 6-diisopropylphenoxymagnesium hydride, lithium tri-t-butoxy aluminum hydride or the like in a solvent such as diethylether, tetrahydrofuran, toluene, dimethylforamide. hexamethylphosphoramide, 2-propanol, ethanol, pentane, or mixtures of any of the above, or the like at a temperature of from -780 to 250C. The reaction can conveniently be conducted in the presence of an added complexing salt such as potassium iodide, magnesium bromide, or the like. Lithium. triEsec-butyl)borohydride is preferred since it yields 4 in predominantly the desired trans-R form. It should be noted that the desired trans-R form can be separated from contaminating trans-S in the 4 mixture by crystallization or chromatography. Further, it should be noted that the above described oxidation-reduction scheme can be repeated on mixed products jL to enhance concentration of trans-R. The acylation 1- > 3 is accomplished by treating with two or more equivalents of a base such as lithium diisopropylamide, lithium hexamethyldisilizide, mesitylithium, lithium 2,2,6,6-tetramethylpyridide or the like in a solvent such as tetrahydrofuran, diethylether, dimethoxyethane or the like at a temperature of from -100 to -200C with an alkylating agent such as N-acetyl imidazole and other activated acylating agents such as thiol esters of acetic acid: EMI10.1 wherein R is alkyl having from 1-6 carbon atoms, phenyl and phenylalkyl; acetic acid halides such as EMI11.1 acetic anhydride; and mixed anhydrides such as: EMI11.2 wherein R is alkyl having 1-6 carbon atoms. Addition of the 1 plus base mixture to the acylating agent is preferred. In the foregoing word description of the process of the present invention, it is to be understood that there is considerable latitude in selection of precise reaction parameters. Suggestion of this latitude and its breadth is generally indicated by the enumeration of equivalent solvent systems, temperature ranges, protecting groups, and range of identities of involved reagents. Further, it is to be understood that the presentation of the synthetic scheme as comprising distinct steps in a given sequence is more in the nature of a descriptive convenience than as a necessary requirement; for one will recognize that the mechanically dissected scheme represents a unified scheme of synthesis and that certain steps, in actual practice, are capable of being merged, conducted simultaneously, or effected in a reverse sequence without materially altering the progress of synthesis. The following examples recite a precise scheme of total synthesis. It is to be understood that the purpose of this recitation is to further illustrate the total synthesis and not to impose any limitation. EXAMPLE 1 (6RS, 7RS)-2,2-Dimethyl-7-acetyl-1-aza-3-oxabycyclo[4.2.0]octan-8-one EMI12.1 A solution of anhydrous dimethyl sulioxide (4.14 ml, 58.4 mMol) in anhydrous methylene chloride (SOml) is cooled to-78tC. under a nitrogen atmosphere. Trifluoroacetic anhydride (6.19 ml, 43.8 mMol) is added to this solution, producing a white precipite in Ca. 5 min. After stirring for a period of 20 min, a solution of 2,2-dimethyl-7-(1-hydroxyethyl)-1-aza3-oxabicyclo[4.2.0]octan-8-one (5.7 g, 29.2 mMol) as a mixture of four diasteromers in anhydrous methylene chloride (50 ml) is added, producing a homogeneous reaction mixture which is stirred for a period of 30 min. Triethylamine (11.37 ml, 81.8 mMol) is then added and the cooling bath is removed. Stirring is continued for an additional 40 min. and then the reaction is worked up (H2O(3x50ml), brine, MgS04) to give 5.2g of crude product. Prior to chromato graph, this material is filtered through a bed of silica gel (52 g) in a 350 ml sinteres-glass funnel, washing with 5% ethyl acetate/methylene chloride High-pressure liguid chromatography of the recovered material using one PrepPAK -500/silica cartridge and eluting with 9% ethyl acetate/methylene chloride affords 3.7 g of crystalline 6RS, 7SR)-2,2dimethyl-7-acetyl-1-aza-3-oxa-bicyclo[4,2,0]octan8-one. Recrystallization from Ca. 1:1 hot ether/ pentane provides analytically pure material: m.p. 73-4 C.; IR(Nujol mull) 5.72, 5.86; NMR(CDCl3) 1.42 and 1.72 (two 8, gem di-CH3's), 1.7-1.9 (m, CHCH2), 2.30 (s, CH3CO), 3.8-4.1(m, CHCHCH2CH2); Anal. (C10H16NO3) C(+0.06), H(-0.28), N(-0.31). EXAMPLE 2 (6RS, 7SR)- 2,2-imethyl-7-acetyl-1-aza-3-oxabicyclo [4.2.0]octan-8-one EMI13.1 A solution of 2,2-dimethyl-l-aza-3-oxabicyclo[4,2.0j- octan-8-one (211 mg, 1.36 mMol) in 2 ml of anhydrous tetrahydrofuran is added to a solution of freshly prepared lithium diisopropylamide (2.72 mMol) in 12 ml of anhydrous tetrahydrofuran at -780C under a nitrogen atmosphere. The resulting lithium enolate solution is stirred for a period of 3 min and then the solution is transferred, under positive nitrogen pressure via spaghetti tubing, to a solution of N- acetylimidazole (299 mg, 2.72 mMol) in 10 ml of anhydrous tetrahydrofuran at -780C under a nitrogen atmosphere. The transfer is completed in ca. 3 min. producing a white precipitate. The cooling bath is removed and stirring is continued for a period of 9 min. Saturated aqueous ammonium chloride (8 ml) is added to the pale yellow solution. Workup (Et2O 25 ml), H2O (8 ml, 3x15 ml), brine, MgS04) gives 116 mg of (6RS, 7RS) - 2,2-dimethyl-7-acetyl-1-aza-3-oxabicyclo[4.2.0]octan-8-one, identical to the same material prepared in a different manner in Example 1. EXAMPLE 3 (6RS, 7SR)- 2,2-Dimethyl-7- ((1RS) -l-hydroxyethyl)1-aza-3-oxabicyclo[4.2.0]octan-8-one EMI14.1 A 0.5 M solution of potassium tri-sec-butylborohydride (950 iil, .475 mMol) in tetrahydrofuran is added to a mixture of (6RS, 7SR)-2,2-dimethyl-7-acetyl-l- aza-3-oxabicyclo[4.2.0]octan-8-one (39 mg, .198mMol) and anhydrous potassium iodide (33 mg, .198 mMOl) in 2 ml of anhydrous ether at 25 C under a nitrogen atmosphere. The mixture is stirred for a period of 2 1/2 h. Glacial acetic acid (54 l, 950 mMol) is added. The resulting mixture is diluted with 10 ml of ethyl acetate and filtered through a bed of Supercel, washing with additional ethyl acetate. The filtrate is concentrated in vacuo to give an oil. Plate-layer chromatography on silica gel (5% CH3oH/CH2 C12) provides 32 mg of an 88:12 mixture of (6RS, 7SR)- 2,2-dimethyl-7-((1RS)-1-hydroxyethyl)-1-aza-3-oxa bicyclo (4.2.0)octan-8-one and (6RS, 7SR)-2,2-dimeth- yl-7- ((lSR)-l-hydroxyethyl) -l-aza-3-oxabicyclo [4.2.0]- octan-8-one, respectively: 300 MHz ;NMR(acetone-d6) # 1.22 (d, J=6.5Hz,CH3CH major isomer), 1.23 (d,J= 6.5Hz, CH3CH minor isomer), 1.38 and 1.62 (two s,gem di-CH3's), 1.88 and 1.92 (two m, CHCH2) 2.69 (dd,J= 1.5 and 7Hz, H7 minor isomer), 2.85 (dd,J=1.5 and 4.5Hz minor isomer), 2.88 (broad s, OH major isomer, shifts upfield at probe temperature of 40 C), 2.92 (broad s, OH minor isomer, shifts upfield at probe temperature of 400C), 3.6 (m, H6 major isomer), 3.7-4.0 (m, H6 minor isomer and Ch'20 and CHOH major isomer), 4.1 (m, CHOH minor isomer). Following the procedure of Examples 1-3, except substituting an equivalent amount of azetidinone 1 (below) for the starting azetidinone of Example 1, there is obtained product 2. EMI15.1 EXAMPLE 4 1-(t-Butyldimethylsilyl)-4-vinylazzetidin-2-one EMI16.1 Triethylamine (5.20 ml, 37.4 mMol) is added to a solution of 4-vinylazetidin-2-one (3.30 g, 34.0 mMol) and t-butyldimethylchlorosilane (5.39g, 35.7 mMol) in 30 ml of anhydrous N,N-dimethylformamide cooled to 0 C. The ice bath is removed and the reaction mixture is stirred for a periqd of 1 h. Workup (Et2O (100 ml), H"O(4x50 ml), brine, MgSO4) gives 7.2 g of a straw-colored liquid. Distillation provides 5.6g of 1-(t-butyldimethylsilyl)-4-vinylazetidin-2-one: b.p. 69 /. 5mm: NMR (CDCl3)#.18 and .23 (two s, Si(CH3)2), .98 (5, t-BuSi), 2.73 (dd,J -15Hz ¯ gem Jtrans-3Hz, H3), 5.55 (dd, Jgem-15Hz, Jcis-6Hz, H3), 4.07 (ddd(7-line m), Jvinyl=8HZ, Jcis= 6Hz, Jtrans= 3Hz,H4), 5.1-6.2 (m, CH=CH2). Anal. (C11H21NOSi) C(+0.25), H(+0.23), N(0.00). EXAMPLE 5 1-(t-butyldimethylsilyl)-3-(-hydroxyethyl) 4-vinvlazetidin-2-one EMI17.1 A solution of l-(t-butyldimethylsilyl)-4-vinyl-2azetidinone (1.50g, 7.11 mMol) in 5 ml of anhydrous tetrahydrofuran is added to a solution of freshly prepared lithium diisopropylamide (7.82 mMol) in 36 ml of anhydrous tetrahydrofuran at -78 C under a nitrogen atmosphere. The resulting lithium enolate solution is aged for a period of 16 min and then acetaldehyde (1.59 ml, 28.4 mMOl) is added. After stirring for an additional 10 min, saturated aqueous ammonium chloride solution (30 ml) is added and the cooling bath is removed. Workup (EtOAc (50 ml, 25 ml), brine MgSO4) provides a yellow oil which is chromatographed on silica gel. Elution with 10% ethyl acetate/chloroform gives 1.75g of 1- (t- butyldimethylsilyl) -3- (l-hydroxyethyl) -4-vinylazetidin- 2-one as a mixture of four diasteromers: IR(CH2Cl2) 5.80; 300MHz NMR(CDCl3)#:-17 and . 23 (two s; Si(CH3)2), .95 (s, t-BuSi), 1.20-1.38 (m, CH3CH) 2.94 (dd, J=7*2 and 2.9Hz, H3), 2.99 (dd, J=5.3 and 2.9Hz, H3), 3.33 (dd, J=7.6 and 6.1Hz, H H3), , 3.41 (dd, J=9.6 and 5.9Hz, H3) 3.86 (dd, J=8.7 and 2.9Hz, H4), 3.98-4.27 (m, CH3CHOH + H4), 5.18-5.50 m, CH=CH2), 5.84-6.10 (m, CH=CH2). EXAMPLE 6 (3S R, 4R S)-l-(t-Butyldimethylsilyl)-3-acetyl-4vinylazetidin-2-one EMI18.1 A solution of l-(t-butyldimethylsilyl)-4-vinylazatidin-2-one (127 mg, .602 mMol) in 1 ml of anhydrous tetrahydrofuran is added to a solution of freshly prepared lithium diisopropylamide (1.20 mMol), in 8 ml of anhydrous tetrahydrofuran at -780C under a nitrogen atmosphere. The resulting lithium enolate solution is stirred for a period of 3 min. The solution is then transferred, under positive nitrogen pressure via spaghetti tubing, to a solution of N-acetyl imidazole (132 mg., 1.20 mMol) in 2 ml of anhydrous tetrahydrofuran at -780C under a nitrogen atmosphere. The transfer is completed in Ca. 2 min. The cooling bath is then removed and stirring is continued an addition 2 min giving a homogeneous solution. Saturated aqueous ammonium chloride (6 ml) is added. Workup (Et2O (10 ml), H20 (6 ml, 9 ml), brine, MgSO4) gives 145 mg of a colorless oil. This material is taken up in a 1:9 ether/petroleum ether and the solution is filtered through a bed of silica gel, washing with additional ether/petroleum ether. The filtrate is evaporated in vacuo to give 91 mg of (3 SR, 4RS)-l-(t-butyldimethylsilyl) 3-acetyl-4-vinylazetidin-2-one: IR(CH2C12) 5.73, 5.83; NMR(CDC13) .17 and .23 (twos, Si(CH3)2), .97 (s, t-BuSi), 2.30 (s, CH3CO), 3.98(d, J=3.5Hz, H3), 4.43 (dd, J=2.5 and 8Hz, H4), 5.10-5.50 (m, CH=CH2), 5.62-6.18 (m, CH=CH2); mass spectrumm/e 196 (M-57). EXAMPLE 7 (3SR, 4SR)-1-(t-Butyldimethylsilyl)-3-acetyl-4 vinylazetidin-2-one EMI19.1 Following the procedure of Example 1, except making the indicated substitution of azetidinone starting material (an equivalent amount), there is obtained (3SRs 4RS)-1- (t-Butyldiemthylsilyl)-3-acetyl-4-vinylazetidin-2-one, which is equivalent in all respects to the identical product of Example 6, above. EXAMPLE 8 (3SR, 4SR)-1-(t-Butyldimethy)-3-(1RS)-1 hydroxyethyl) -4-vinylazetidin-2-one EMI20.1 A 0.5M solution of potassium tri-sec-butylborohydride (739 l, .370 mmol) in tetrahydrofuran is added to a mixture of (3SR, 4Bi)-l-(t-butyldimethyl- silyl)-3-acetyl-4-vinylazetidin-2-one (39 mg, .154 mmol) and anhydrous potassium iodide (26 mg, .154 mmol) in 1.5 ml of anhydrous ether at 250C under a nitrogen atmosphere. The mixture is stirred for a period of 2 hours. Glacial acetic acid (21 ijl, .370 mmol) is then added. The resulting mixture is diluted with 10 ml of ethyl acetate and filtered through a bed of Supercel, washing with additional ethyl acetate. The filtrate is concentrated in vacuo to give crude product, This material is purified by plate-layer chromatography on silica gel (5% CH20H/CH2C12) to give 31 mg of a crystalline mixture in the ratio of 85:15 of (3SR, 4SR)-1-(t-butyldimethylsilyl)-3-((1RS)-1hydroxyethyl)-4-vinylazetidin-2-one nad (3SR, 4SR)-1-(b-butyldimethylsilyl)-3-((1SR) 1-hydroxyethyl)-4-vinylazetidin-2-one, respectively: 300MHz nmr (CDCl3)#.14 and .22 (two s, Si(CH3)2), .92(s, SiC(CH3)3), 1.22 (d, J=6Hz, CH3CH major isomer), 1.28 (d, J=6Hz, CH3CH minor isomer), 2.04 (d, J=5Hz, OH major isomer), 2.33 (d, J=5Hz, OH minor isomer), 2.92 (dd, J=2.5 and 6.8 Hz, H3 minor isomer), 2.97 (dd, J=2.5 and 5.2Hz, H3 major isomer), 3.84 (dd, J=2.5 and 8.7Hz, H4 minor isomer), 4.09 (dd, J=2.5 and 9Hz, H4 major isomer), 4.2 (m, CH3CH), 5,14-5.34 (m, CH=CH2), 5.9 (m, CH=CH2). EXAMPLE 9 1-(t-Butildimethylsilyl)-3-(1-hydroxyethyl)-4 (prop-2-ene > azetidin-2-one EMI22.1 n-Butyllithium in hexane (26.25 mmol) is added slowly by syringe to a solution of diisopropylamine (26.25 mmol) in anhydrous tetrahydrofuran (100 ml) at -780C. The resulting solution is stirred for 15 min prior to the addition of a solution of 1-(t-butyldimethylsilyl)-4-(prop-2-ene)-azetidin-2one (25.0 mmol) in anhydrous tetrahydrofuran (25 ml). After stirring for 15 min at -780C, acetaldehyde (75 mmol) is added by syringe and the resulting solution is stirred at -780C for 5 min. Saturated aqueous ammonium chloride solution (15 ml) is added by syringe and the reaction mixture is allowed to warm to room temperature, then diluted with ether (250 ml) and washed with 2.5N hyarochloric acid solution (2 x 50 ml), water (100 ml) and brine and dried over magnesium sulfate. Solvents are removed in vacuo and -he semi-solid residue is chronatographed on silica gel (1:1, ether:petroleum ether). The first product to elute is the cis R compound (688 mg) n.m.r. (CDC13+D20)g 4.8 - 6.2 (3H, m, loefinic), #4.2 (lH, d# J= 6.5, 3.7, H-8), #3.75 (1H, ddd, J=5.5, 5, 4.8, H-5) #3.28 (H, dd, J=5.5, 3.7, H-6), #2.2-3.0 (2H, m, allyl), #1.35 (3H, d, J=6.5, CH3-CHOH), #1.0 (9H, S,+Si-), #0.3(6H,S, (CH3)2Si). The second fraction is a mixture of the trans R and S products (.56 g). Crystallization of this material from petroleum ether gives the pure trans R material, m.p. 61-82 C. IR (CHCl3) 3400, 2920, 2850, 1723 cm ; n.m.r. (CDCl3 + D2O)#4.9-6.2 (3H, m, olefinic),#4.1 (1H, dq, J= 7.0, 6.8, H8), #3.66 (1H, ddd, J= 11, 4.5, 3.0, H5), # 2.9 81H, dd, J=6.8, 3.0, H6)#1.8-2.8 (2H, m, ally), #1.26 (3H, d, J=7.0, CH3-), #1.0 (9H, S, +Si), 0.28 (6H, 2S, (CH3)2Si). EXAMPLE 10 1- Ct-Butyldimethyls ilyl)-3-(l-oxoethyl )-4-(prop- 2-ene)-azetidin-2-one EMI24.1 A. Trifluoroacetic anhydride C7.5 mmol) is added dropwise by syringe to a solution of dimethylsulfoxide (10 mmol) in anhydrous methylene chloride (15 ml) at -780C. The resulting mixture is stirred at -780C for 20 min. during which time a white precipitate forms. A solution of 1- (t-butyldimethylsl) -3-(1-hydroxyethyl)- 4-(prop-2-ene)-azetidin-2-one (5.0 mmol) in methylene chloride (1S ml) is added by syringe and the resulting solution is stirred at -780C for 30 min. Triethylamine (14 mmol) is added by syringe and the cooling bath is removed. After an additional 1 hr., the reaction mixture is diluted with methylene chloride (100 ml), washed with WkE (50 ml) and brine and dried over magnesium sulfate. Removal of solvents in vacuo yields an oil which is chromatographed on silica gel (2:1, petroleum ehter: ether) to yield 1-(t-butyldimethylsilyl-3-(1- oxoethyl)-4-(prop-2-ene)-azetidin-2-one. I.R. (CHCl3) 2925, 2855, 1734, 1705 cm n.m.r. (CDCl3)# 4.8-6.1 (3H, m, olefinic)#3.8-4.2 (2H, overlapping multiplets, H5, H6), #2.0-2.9 (2H, m, allylic), # 2.3 (3H, S, CH3-C) #0.96 (9H, S, + Si-), #0.25 (6H, 2S, (CH3)2Si). Mass spectrum m/e 267 (m+) 252, 226, 210. EMI25.1 B. n-Butyllithium in hexane (4.10 mmol) is added by syringe to a solution of diisopropylamine (4 10 mmol) in anhydrous tetrahydrofuran (1S ml) at -78 C. The resulting solution is stirred at -78 C for 15 min. prior to the addition of a solution of 1-(t-butyl- dimethylsilyl)-4-(prop-2-ene)-azetidin-2-one (2.0 mmol) in anhydrous tetrahydrofuran (2 ml). After an additional 15 min. at -780C, the reaction mixture is added via a Teflon tube to a mixture of N-acetylimidazole (4.1 mmol) in anhydrous tetrahydrofuran (16 tal) at -780C. The resulting yellow reaction mixture is stirred at -78 C for 15 min, then quenched by addition of saturated aqueous ammonium chloride solution (10 ml). The reaction mixture is diluted with ether (100 ml) and washed with 2.5N hydrochloric acid solution (25 ml) water (25 ml) and brine. The organic phase is dried over magnesium sulfate and concentrated in vacuo to yield an oil. This maternal is chromatographed on silica gel (2:1 petroleum ether:ether) to yield l-(t-butyldimethyl- silyl)-3- oxoethyl)-4-(prop-2-ene)-azetidin-2-one. EXAMPLE li 1-(t-Butyldimethylsilyl)-3-(1-hydroxyethyl)-4 (prop-2-ene) azetidin-2-one EMI26.1 K-Selectride (potassium tri-(sec)-butylborohydride) in tetrahydrofuran (4.8 mmol) is added by syringe to a mixture of potassium iodide (2.0 mmol) and l-(t-butyldimethylsilyl)-3-(1-oxoethyl)-4"(prop-2-ene)- azetidin-2-one (2.0 mmol) in anhydrous ether (20 ml) at room temperature. The resulting mixture is stirred at room temperature for 2.5 hours, then quenched by addition of glacial acetic acid (9.6 mmol). The resulting mixture is diluted with ethylacetate (100 1) and filtered tnrough celite. Removal of solvents in vacuo gives an oil whicn is chromatographed on silica gel (1:1 ethar:petroleum ether) to yield 1.90 g (95%) of 1-(t-Butyldimethylsilyl)-3-(1-hydreoxyethyl) -4-(prop-2-ene)-azetidin-2-one as a white solid. N.M.R. examination of this material indicates the R/S ratio to be > 5/1. Tne R isomer is isolated by crystallization from petroleum ether. Following the procedure of Examples 9-11, except substituting an equivalent amount of azetidinone 1 (below) for the azetidinone starting material of Example 9, there is obtained the corresponding product 2: EMI26.2 = CH3, CH3CH2, CH2# R = CH3, CH3CH2, CH2# (# = phenyl) respectively. EXAMPLE I2 (3,R,S,2R)-1-(t-Butyldimethylsilyl)-3-[(R,S)-1 hydroxyethyl]-4-E2,2-(trimethylenedithia)-2- trimethylsilylethyl]-azetidin-2-one EMI27.1 A solution of diisopropylamine (10.5 mmol) in anhydrous tetrahydrofuran (40ml) is cooled to -78 C (dry ice-acetone) and stirred under nitrogen atmosphere while n-butyllithium in hexane (10.5 mmol) is added slowly by syringe. After 15 min., a solution of (4S)-l-(t-butyldimethylsilyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilyl ethyl]-azetidin- 2-one (10.0 mmol) in anhydrous tetrahydrofuran (12ml) is added slowly by syringe. The resulting solution is stirred at -78 C for 20 min. prior to the addition of acetaldehyde (30.0 mmol). After an additional 10 min. at -78 C the reaction is quenched by the addition of saturated aqueous ammonium chloride solution (10 ml) and allowed to warm to room temperature. The reaction mixture is diluted with ethyl acetate (150 ml) and washed with 2.5N hydrochloric acid solution (50 ml), water (50 ml) and brine (50ml) and dried over magnesium sulfate. Removal of solvents in vacuo gives a white solid (4.6g) which is chromatographed on 250g of silica gel (1:1, ether: petroleum ether) to give four main product fractions with a total weight of 4.185g (96.7e). Fraction No. 1-R=0.62, 85mg. Fraction No. 2 Rf=0.43, 1.95g (458), (3s,4R)-l-(t-butyldimethyl-silyl) 3-[(S)-1-hydroxyethyl]-4-[2,2-(trimethylenedithia-]-2-tri methylsilylethyl]-azetidin-2-one. Fraction No. 3-R= 0.34, 150 mg. mixture. Fraction No. 4-Rf=0.28, 2.0g (46%), (3S,4R)-1-(tributyldimethylsilyl)-3-[(R)-1hyroxyethyl]-4-[2,2-(trimethylenedithiy)-2-trimethyl silylethyl] -azetidin-2-one. E 13 (3S, 4R9-1-(t-Butyldimethylsilyl)-3-(1-oxoethyl)-4 [2,2-(trimethylenedithia)-2-trimethylsilylethyl)azetidin-2-one Step A: EMI29.1 A solution of diisopropylamnne (6.0 mmol) in anhydrous tetrahydrofuran (25 ml) is cooled to -780C (dry ice-acetone) and stirred under a nitrogen atmosphere while n-butyllithium in hexane (6.0 mmol) is added by syringe. After 15 min, a solution of (4S)-1-(t-butyldimethylsilyl)-4-[2,2-(trimethylendithia)2-trimethylsilylethyl]-azetidien-2-one (3.0 mmol) in anhydrous tetrahydrofuran (3 ml) is added dropwise by syringe. The resulting solution is stirred at -78eC or 30 min., then added through a Teflon tube to a mixture of N-acetylimidazole (6.0 mmol) and anhydrous tetrahydrofuran (25 ml) at -78 C. The resulting yellow reaction mixture is stirred at -780C for 10 min., then quenched by addition of saturated aqueous ammonium chloride solution. The reaction mixture is poured into ether (200 ml) and extracted with 2.5N hydrochloric acid solution(50 ml), water (50 ml) and brine and dried over magnesium sulfate. Removal of solvents in vacuo gives a yellow oil which is chromatographed on silica gel tether-petroleum ether) (1:2) to yield (3s,4R)-l-(t-butyl- dimethylsilyl) -3- (1-oxoethyl) -4- [2,2- (trimethylenedithia) 2-trimetysilylethyl3 -azetidin-2-one. Step B: EMI30.1 Trifluoroacetic anhydride (6.0 mmol) is added by syringe to a solution of dimethylsulfoxide (8.0 mmol) in anhydrous methylene chloride (10 ml) at -780C. The resulting mixture is stirred at -78oC for 20 min., during which time a white precipitate forms. A solution of (3RS, 4R)-1-(t-butyldimethylsilyl)-3-(RS-1hydroxyethyl)-4-[2,2-(trimethilenedithia)-2-trimethylsilylethyll-azetidin-2-one (4.0 mmol) in anhydrous methylene chloride (10 ml) is added by syringe and the resulting mixture is stirred at -780C for 40 min. Triethylainine (11.2 mmole) is added by syringe and the cooling bath is removed. After 1 hr. the reaction mixture is diluted with CH2C12 (100 ml) and washed with 2.SN hydrochloric acid solution (50 ml), water (50 ml) and brine and dried over magnesium sulfate. Purification as above yields (3S, 4R)-1-(t-butyldimethylsilyl)-3- (1-oxoethyl)-4-[2,2-trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one. n.m.r. (CDcl3) 4.23 (1H, BrS, H-6), #4.2 (1H, m, H-5),52.1-3.2 (6H, m), #2.27 (3H, S, CH3-C=O), #2.0 (2H, m, SCH2CH2CH2S), #0.96 (9H, S,#Si), #0.25 (15H, br.S (CH3)2Si & (CH3)3Si). EXAMPLE 14 (3S, 4R)-1-(t-Butyldimethylsilyl)-3-[(R)-1-hydroxyethyl]-4-[2,2.-(trimethylenedithia-2-trimethylsilylethyllazetidin-2-one EMI31.1 K-Selectride Cpotassium tri-sec-butylborohydride) (4.8 mmol) in a solution of tetrahydrofuran is added dropwise by syring to a mixture of (3S, 4R)-l- (t-butyldimethylsilyl)-3-(1-oxoethyl)-4-t2,2-(trimethylenedithia)-2-trimethylsilylethyl9-azetidin-2-one (2.0 mmol) and potassium iodide (2.0 mmol) in anhydrous ether (20 ml) at room temperature. The resulting mixture is stirred at room temperature for 2.5 hr., then quneched by addition of glacial acetic acid (9.6 mmol). The resulting mixture is diluted with ethyl acetate (50 ml) and filtered through celite. The solvents are removed in vacuo to give an oil which is chromatographed on silica gel (1:1, ether: petroleum ether) to give (3S,4R)-1 (t-butyldimethylsilyl)-3-[(R)-1-hydroxyethyl]-4-[2,2 (trimethylenedithia)-2-trimethylsilylethyll-2z etidin-2one as a white solid, n,m,r. (CDC13+D20) #4.23 (1H, dq, J= 7.5, H-8)#3.78 (1H, ddd, J=7.5, 3, 2.2, H-5) #3.18 (1H, dd, 7.5, 2.2, H-6), #2.5-3.0 (4H. m. SCH2CH2CH2S- #2.35 (2H, m, -CH2 #2.0 (2H, m, SCH2Ch2Ch2S) #1.33 EMI31.2 CH3-), 60.98 (9H S, #Si)#0.26 (15H, br.S, (CH3)2 Si + (CH3)3Si)

Claims: WHAT IS CLAIMED IS 1. A process for preparing: EMI32.1 comprising treating: EMI32.2 with an acetylating agent to yield: EMI32.3 followed by treating with a reducing agent; wherein R1 is selected from: CH=CH2 CH2CH=CH2 CH2CH=CHR EMI32.4 (any single pair of Ra, Rb or RC may be joined to form (CH2)3 ) (Ra and Rb may be joined to form -(CH2)3-; R@ values independently chosen) (joinder of RÚ and Rê) wherein Rê and R are independently selected from hydrogen or a protecting group; Ra, Rb and Rc are independently selected from: alkyl, aryl and aralkyl wherein the aryl is phenyl and the alkyl has 1-6 carbon atoms; and R is alkyl having 1-6 carbon atoms, phenylalkyl having 7-12 carbon atoms, cycloalkyl having 3-6 carbon atoms, and cycloalkylalkyl having 4-12 carbon atoms; R9 and Rh are independently selected from alkyl having 1-6 carbon atoms; R5 and Rh may be joined to form, counting the carbon atom to which they are attached, a carbocyclic ring having 3-6 carbon atoms. 2. A process according to Claim 1 wherein R2 is hydrogen or a triorganosilyl protecting group: RdReRfSi wherein Rd, Re and Rf are independently selected from alkyl having 1-6 carbon atoms; and wherein Rq, Rb and Rc are independently selcted from the group consisting of alkyl having 1-6 carbon atoms, phenyl and alkylphenyl having 7-12 carbon atoms. 3. A process according to Claim 1 wherein the acetylating agent is N-acetyl imidazole. 4. A process according to Claims 2 or 3 wherein This triorganosilyl. 5. A process for preparing: EMI34.1 comprising treating: EMI34.2 with an oxidizing agent to yield: EMI34.3 followed by treating with a reducing agent; wherein R1 is selected from: CH=CH2 CH2CH=CH2 CH2CH=CHR EMI34.4 Cany single pair of Ra, Rb or Rc may be joined to form -(CH2)3) (Ra and Rb may be joined to form -(CH2)3-; Rc values independently chosen) (joinder of R1 and R2) 6. A process according to Claim 4 wherein R2 is hydrogen or a triorganosilyl protecting group: RdReRfSi- wherein d Re and Rf are independently selected from alkyl having 1-6 carbon atoms; and wherein Ra, Rb and Rc are independently selected form the group consisting of alkyl having 1-6 carbon atoms, phenyl and alkylphenyl having 7-12 carbon atoms. 7. A process according to Claims 5 or 6 wherein R2 is triorganosilyl. 8. A process according to Claims 1-6 or 7 1. wherein R is a member of the group consisting of CH=CH2 CH2CH=CH2 EMI35.1 and EMI35.2 9. A process according to Claims 1-6 or 7 for preparing: EMI35.3 10. A process according to Claim 8 wherein R1 is EMI36.1

Inventors: BOUFFARD, AILEEN F., CHRISTENSEN, BURTON G., RATCLIFFE, RONALD W., SALZMANN, THOMAS N.
Applicants: MERCK & CO. INC.
Application year: 1980
Main classification: C07D205
IPC codes: C07D205, C07D405, C07D505, C07D498, C07F7